STK11 and pancreatic neoplasm: Although more mechanistic studies are required to understand the relationship between STK11 and PDEs in the progression of PDAC, the results reported herein also indicate a potential path for therapeutic intervention with Roflumilast for STK11 mutant pancreatic cancer patients.